CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Pfizer
Amgen
Pfizer
Amgen
BioNTech SE
Lyell Immunopharma, Inc.
BeOne Medicines
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Immatics US, Inc.
Genmab
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Janssen Research & Development, LLC
Beijing Biotech
AVEO Pharmaceuticals, Inc.
Alpha Tau Medical LTD.
SecuraBio
ModernaTX, Inc.
Hoffmann-La Roche
ModernaTX, Inc.
AstraZeneca
IDEAYA Biosciences
Novartis
Genentech, Inc.
Regeneron Pharmaceuticals
Telix Pharmaceuticals (Innovations) Pty Limited
Keystone Nano, Inc
Hoffmann-La Roche
Prescient Therapeutics, Ltd.
Amgen
Beijing Biotech
Pfizer
AstraZeneca
Treeline Biosciences, Inc.
Sumitomo Pharma America, Inc.
Celgene
Acrivon Therapeutics
Regeneron Pharmaceuticals
Verity Pharmaceuticals Inc.
Orano Med LLC
Daiichi Sankyo
MSD R&D (China) Co., Ltd.
Beijing Biotech
Beijing Biotech
Ratio Therapeutics, Inc.
AstraZeneca
Vanda Pharmaceuticals
Sellas Life Sciences Group
Jiangsu Simcere Pharmaceutical Co., Ltd.